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Baltimore, Maryland 
Amiodarone is an investigational antiarrhythmic agent 
known to cause pulmonary toxicity. This report de•
scribes two patients with previous amiodarone pulmo•
nary toxicity and complete resolution who at rechallenge 
5 to 6 months later developed within 2 weeks of therapy 
a significant reduction in lung diffusion capacity before 
Amiodarone, a benzofuran derivative structurally similar to 
thyroxine with potent antiarrhythmic characteristics (1), has 
been reported (2,3) to cause pulmonary toxicity. Pulmonary 
function tests in patients with clinical amiodarone pulmo•
nary toxicity have revealed hypoxia and restrictive changes 
with reduction in total lung capacity and diffusion capacity. 
Some investigators (4,5) noted a predisposition to pulmo•
nary toxicity in patients with preexisting impairment in dif•
fusion capacity. Other investigators (3) found no consistent 
or predictive changes. We report on two patients with pre•
vious amiodarone pulmonary toxicity and complete reso•
lution whose incessant arrhythmias necessitated rechallenge 
with amiodarone 5 to 6 months later, resulting in significant 
reduction in pUlmonary diffusion capacity within the first 2 
weeks of therapy before overt signs or symptoms of toxicity 
recurred. This suggests that amiodarone pulmonary toxicity 
may first present with a reduction in diffusion capacity be•
fore clinical toxicity develops and that serial diffusion ca•
pacity testing may signal the need to alter treatment early 
in the course of amiodarone therapy. 
Case Reports 
Case 1 
A 60 year old black woman with recurrent, refractory 
ventricular tachycardia was treated with amiodarone from 
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overt clinical toxicity occurred. This suggests that tox•
icity may present early with reduction in diffusion ca•
pacity and that such changes may warrant the need to 
alter treatment. 
(J Am Coli CardioI198S;6:802-S) 
March 2 to June 17, 1983 (loading dose 1,200 mg/day for 
14 days, 400 mg/day for 1 week and then 200 mg/day 
maintenance). Treatment was terminated on June 17 because 
of insidious development of dyspnea, hypoxia and pulmo•
nary infiltrates (Fig. lA), culminating in severe respiratory 
embarassment necessitating transient respirator depen•
dency. After amiodarone was discontinued, short-term cor•
ticosteroid therapy was instituted, pUlmonary function re•
turned to normal and the chest X-ray film cleared after 1 to 
2 weeks. 
The patient was readmitted on January 15, 1984 because 
of recurrent, incessant ventricular tachycardia. Because of 
failure with all conventional antiarrhythmic agents and sev•
eral investigational agents, amiodarone was restarted at a 
low dose (100 mg/day) on January 18, 1984 after informed 
consent had been obtained. Baseline chest X-ray film and 
pulmonary function tests performed before amiodarone re•
challenge are shown in Figure IB and Table 1, respectively. 
After 1 week of therapy, nonsustained ventricular tachy•
cardia persisted and thus the dose was increased to 600 
mg/day for another week. During this 2 week therapy with 
amiodarone, there was no evidence of respiratory infection 
or congestive heart failure and no change in the patient's 
weight or other medication. Although the patient had no 
respiratory symptoms and repeat chest X-ray film (Fig. Ie) 
at the end of the second week of amiodarone therapy was 
not significantly changed from the baseline film, repeat pul•
monary function tests revealed a significant reduction in 
diffusion capacity to 67% of predicted value (50% reduc•
tion). Amiodarone was discontinued and corticosteroid ther•
apy was instituted (prednisone, 40 mg/day administered over 
1 week). On the following day, the patient developed mild 
to moderate dyspnea with no change in arterial blood gases 
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Figure 1. Case 1. Chest X-ray films obtained (A) in 1983 when 
amiodarone pulmonary toxicity was evident, (B) in 1984, before 
amiodarone was reinstituted and (C) 2 weeks after amiodarone 
rechallenge, when decreased diffusion capacity was present. Ls = 
left supine. 
or repeat chest X-ray film. Repeat pulmonary function tests 
performed 1 week after discontinuation of amiodarone re•
vealed no significant changes despite a slight decrease in 
dyspnea. Repeat pulmonary function tests at 2 weeks re•
vealed significant improvement in diffusion capacity to 88% 
of predicted values (Table 1) and dyspnea had completely 
resolved. 
Case 2 
A 69 year old white woman with documented Wolff•
Parkinson-White syndrome and recurrent, refractory supra•
ventricular tachycardia was treated with amiodarone from 
March 1 to September 23, 1983 (loading dose 1,200 mg/day 
for 14 days and 200 mg/day maintenance dose). Treatment 
was discontinued because of insidious development of dys•
pnea on exertion, scattered areas of interstitial fibrosis on 
chest X-ray film (Fig. 2A) and significant reduction in dif•
fusion capacity to 62% of predicted value from 100% base•
line level. One week after amiodarone was discontinued, 
dyspnea resolved and diffusion capacity had normalized. 
The patient was readmitted on February 8, 1984 because 
of recurrent, incessant supraventricular tachycardia. Treat-
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ment with conventional agents and several investigational 
agents was unsuccessful; therefore, amiodarone was re•
started at a low dose (600 mg/day) after informed consent 
was obtained. Baseline chest X-ray film and pulmonary 
function tests performed before amiodarone rechallenge are 
shown in Figure 2B and Table 1, respectively. Although 
the patient had developed no respiratory symptoms or change 
on repeat chest X-ray film (Fig. 2C) at the end of 1 week 
of therapy, repeat pulmonary function tests revealed a sig•
nificant reduction in diffusion capacity to 62% of predicted 
value (43% reduction). Mild hypoxia was also noted, though 
the patient remained asymptomatic while confined to bed. 
During therapy with amiodarone, there was no evidence of 
respiratory infection, congestive heart failure or changes in 
the patient's weight or other medications. Amiodarone was 
discontinued and corticosteroid therapy was instituted (pred•
nisone, 40 mg/day administered over 1 week). Repeat pul•
monary function tests performed 1 week after amiodarone 
was discontinued revealed significant improvement in dif•
fusion capacity to 82% of predicted valve. 
Discussion 
We report on two patients with previous amiodarone 
pulmonary toxicity and complete resolution in whom amio•
darone rechallenge resulted in significant reduction in dif•
fusion capacity before overt clinical toxicity recurred. The 
Table 1. Serial Pulmonary Function Tests at Baseline, During Therapy and After Discontinuation of Amiodarone 
Case I Case 2 
Amiodarone Therapy Amiodarone Therapy 
Baseline During After Baseline During After 
FYC 2.1 (86%)* 2.6 (104%) 2.4 (99%) 2.7 (82%) 2.9 (89%) 2.6 (80%) 
FEY! 1.8 (90%) 2.0 (100%) 2.0 (100%) 1.9 (73%) 2.0 (77%) 1.8 (70%) 
TLC 4.6(111%) 3.7 (89%) 3.9 (94%) 5.5 (92%) 4.6 (77%) 5.5 (92%) 
DLCO 26 (134%) 13 (67%) 18 (88%) 23 (110%) 13 (62%) 18 (82%) 
P02 85 82 90 94 81 85 
*Percent of predicted values. DLCO = lung diffusion capacity (mllm per mm Hg); FEY! = forced expiratory volume at I second (liters); FYC = 
forced vital capacity (liters); P02 = partial pressure of oxygen at room air (mm Hg); TLC = total lung capacity (liters). 
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Figure 2. Case 2. Chest X-ray films obtained (A) in 1983 when 
amiodarone pulmonary toxicity was evident, (B) in 1984 before 
amiodarone was reinstituted and (C) 1 week after amiodarone 
rechallenge when decreased diffusion capacity was present. i = 
upright. 
degree of reduction in both patients was well beyond the 
accepted 10% variability in diffusion capacity noted in our 
laboratory. To our knowledge, this represents the first such 
observation since amiodarone pUlmonary toxicity was first 
reported by Rotmensch et al. (2). 
Pulmonary function testing. Although pulmonary 
function tests in patients with amiodarone pulmonary tox•
icity have revealed hypoxia and restrictive changes with 
reduction in total lung capacity and diffusion capacity (6,7), 
the value of pulmonary function tests in predicting toxicity 
is controversial. Whereas some investigators (4,5) noted a 
predisposition to pulmonary toxicity in patients with preex•
isting impairment in diffusion capacity «80% of predicted) 
and total lung capacity «80% of predicted values), others 
(3) found no consistent or predictive changes in pulmonary 
function tests. 
Whether exposure to amiodarone itself produces a change 
in diffusion capacity or whether this change is a prelude 
to clinical toxicity is an important question. Our experience 
so far in a prospective study of 16 patients who have been 
treated with amiodarone and received serial diffusion ca•
pacity testing and have not developed clinical pulmonary 
toxicity through a mean of 8 months' follow-up has revealed 
mean maximal changes of 10% from baseline level. These 
changes are within the accepted spontaneous variability noted 
in our laboratory. 
Mechanisms of pulmonary injury. Amiodarone-induced 
pulmonary toxicity is thought to be, at least in part, dose•
related and usually is evident a few months after the start 
of therapy (2,6,8). Our two cases are somewhat unusual in 
that both patients experienced significant changes with such 
low doses and short-term rechallenge. This would suggest 
that a direct toxic effect, hypersensitivity or possibly an 
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immunologic memory cell-mediated mechanism led to early 
loss of effective alveolar-capillary surface area for gas ex•
change. Neither of the two patients had histologic confir•
mation of amiodarone-induced pulmonary toxicity at their 
first or second exposure to the drug and, thus, specific lung 
tissue changes could not be correlated with the physiologic 
impairment noted. 
Although the role of corticosteroids in the treatment of 
amiodarone pulmonary toxicity is controversial, both pa•
tients received prednisone empirically. In one patient there 
was no apparent improvement in diffusion capacity after I 
week of corticosteroid therapy, whereas improvement was 
noted in the other patient, although previous toxicity had 
resolved without corticosteroid intervention. Thus, the role 
of corticosteroids remains unclear. 
Clinical implications. Our observations suggest that 
earliest toxicity from amiodarone may present as asymp•
tomatic significant reduction in diffusion capacity before a 
critical threshold is reached that results in overt clinical 
signs, symptoms or radiologic findings. Such early changes 
should lead to closer surveillance and perhaps result in a 
change in doses or therapy before clinical toxicity can occur. 
Defining subclinical toxicity, as judged by reductions in 
diffusion capacity, would also serve as an avenue to study 
the role of corticosteroids or other interventions on the course 
of toxicity. 
We express our gratitude to Toni Haase for secretarial assistance. 
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